NCT05677893View on ClinicalTrials.gov

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 7, 2022

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
Interventions
DRUG

MBS-COV

MBS-COV is a potent siRNA treatment for mild to moderate COVID-19.

OTHER

Placebo

Normal saline

Trial Locations (1)

90630

Phase I Unit, Los Angeles

Sponsors
All Listed Sponsors
lead

Oneness Biotech Co., Ltd.

INDUSTRY

NCT05677893 - A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants | Biotech Hunter | Biotech Hunter